Trials / Recruiting
RecruitingNCT06568562
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- University of Utah · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants will return to clinic for regular visits for checkups and tests.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL092 | XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle. |
Timeline
- Start date
- 2024-12-09
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2024-08-23
- Last updated
- 2025-12-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06568562. Inclusion in this directory is not an endorsement.